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Asthma in pregnancy poses a risk of adverse outcomes. Osteopontin and clusterin emerged as asthma biomarkers; however, their
circulating levels during pregnancy are unknown yet. This cross-sectional study investigated peripheral osteopontin and clusterin
levels and their relationship to disease control in 26 asthmatic pregnant (AP), 22 asthmatic nonpregnant (ANP), and 25 healthy
pregnant (HP)women and 12 healthy controls (HNP).Osteopontin levels of ANP andHNPwere similar (2.142 [1.483–2.701] versus
2.075 [1.680–2.331] ng/mL, 𝑝 = 0.7331). Pregnancy caused amarked elevation in both healthy (HP: 3.037 [2.439–4.015] ng/ml, 𝑝 =
0.003 versus HNP) and asthmatic (AP: 2.693 [1.581–3.620] ng/ml) patients; thus the pregnant groups did not differ (𝑝 = 0.3541).
Circulating clusterin levels were comparable in ANP and HNP (109.2 [95.59–116.3] versus 108.8 [97.94–115.3] 𝜇g/mL, 𝑝 = 0.8730)
and the level was lower in HP (98.80 [84.26–105.5] 𝜇g/mL, 𝑝 = 0.0344 versus HNP). In contrast, the level was higher in AP (111.7
[98.84–125.6] 𝜇g/mL, 𝑝 = 0.0091 versus HP). In ANP, a positive correlation of PEF (𝑟 = 0.3405; 𝑝 = 0.0221) and a negative
correlation of 𝑅aw (𝑟 = −0.3723; 𝑝 = 0.0128) to clusterin level were detected. Circulating osteopontin level increases in pregnancy
regardless of concomitant well-controlled asthma, indicating its gestational role. Clusterin level decreases in healthy but not in
asthmatic pregnancy and correlates directly with lung function.
1. Introduction
Asthma is one of the most common chronic diseases compli-
cating pregnancy [1, 2], occurring in 8–12% of all gestations
[3]. It represents a risk of potentially serious fetal and
maternal morbidities, such as gestational hypertension, low
birth weight, preeclampsia, preterm delivery, and increased
neonatal mortality [4, 5]. On the other hand, pregnancy
may also influence the control of asthma, leading to the
deterioration of symptoms in one-third of pregnant women
[6]. It is important to note that proper disease control
decreases the risk of adverse pregnancy outcomes [7]; thus
the maintenance of optimal asthma control and identifi-
cation of pregnant women at risk of uncontrolled asthma
are extremely important. However, treating asthma during
pregnancy is a serious challenge for specialists due to the
alterations in immune phenotype [8] and cytokine patterns
[9] and the fact that pregnancy itself can influence spirometry
results [10]. Unfortunately, the available techniques used to
determine specific asthma phenotypes (e.g., induced sputum)
are semi-invasive, and thus they should be avoided during
pregnancy. Therefore, it would be crucial to have clinically
usable biomarkers that can be linked to the loss of asthma
control, which might help to detect the elevated risk of
complications. However, easily obtainable peripheral blood
biomarkers related to deteriorating disease control during
asthmatic pregnancy are still not available.
Osteopontin is a multifunctional extracellular matrix
protein and immunemodulator originally discovered in bone
but later identified in many cell types, such as bronchial
epithelial cells and inflammatory cells around the airways,
including T-cells and eosinophils [11–16]. It has a secreted
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soluble and an intracellular nonsecreted form. As a secreted
acidic glycoprotein [16], it acts both as an extracellular matrix
protein and as a cytokine [17], which plays a role in themigra-
tion of a number of inflammatory cells, including monocytes
[18], lymphocytes [19], and neutrophils [20–22]. Although
osteopontin has been recognized as a key cytokine involved
in Th1 cell dominant immune responses, recent findings
demonstrate that osteopontin levels are also elevated in Th2
cell related conditions, such as asthma and IgE-mediated
allergic diseases. The exact role of osteopontin in allergy is
not fully elucidated, but there are both human-model and
animal-model studies that strongly support the hypothesis
that osteopontin is an effector involved in critical steps of
allergic inflammation [11]. Elevated osteopontin levels were
demonstrated also in the sputum and bronchoalveolar lavage
fluid (BALF) of asthmatic patients compared to the samples
of healthy test subjects, and in these studies the BALF
osteopontin levels showed correlation with the peripheral
eosinophil count [22, 23].
During pregnancy, osteopontin has diverse biological
functions in the uterus from the peri-implantation period
till the end of gestation. It is thought to play a role in the
uteroembryonal synchronization and is associated with the
blastocysts’ implantation competency [24, 25]. The rising
level of osteopontin during pregnancy and its relation to the
number of recruited decidual NK cells [26] suggest that it has
an important role in the maintenance of a successful preg-
nancy. This idea is supported even further by some studies
that detected lower osteopontin levels in pregnant women
with preeclampsia and unexplained recurrent miscarriage
[26, 27].
Clusterin is a multifunctional, stress-induced, ATP-
independent molecular chaperone, expressed in most tissues
and human fluids analyzed [28, 29]. It has two isoforms:
a precursor nuclear form and a secreted extracellular form
[29]; the two forms have been shown to have opposite
functions. The nuclear form is thought to be associated
with the promotion of cell death and apoptosis, while the
secreted form is thought to be upregulated as a protective
response during oxidative stress and endothelial injury [29].
The expression of clusterin is increased in several diseases,
including diabetes, atherosclerosis, and Alzheimer’s disease
[30]. It takes part in the inhibition of complement-membrane
attack complex, protection against inflammation, and cyto-
protection at fluid tissue boundaries [29]. Secreted clusterin
is involved in cancer progression, because, as a chaperon, it
protects cells from varied therapeutic stressors that induce
apoptosis, including radiation, cytotoxic chemotherapy, and
biologic agents [28]. Extracellular clusterin exerts potent
effects on the formation of amyloid in vitro, and it is suggested
that in some circumstances increasing in vivo clusterin levels
could be a therapeutic tool in extracellular protein deposition
disorders [31]. As Carnevali et al. demonstrated, it may have
a protective role against oxidative stress in the airways of
smokers [32]. Circulating clusterin concentration was found
to be elevated in patients with severe asthma, and it showed
an inverse correlation with lung function; however, clusterin
was considered an indicator of oxidative stress rather than a
protective factor [30]. It also correlated with the age of the
patients and showed a significant decrease in steroid-naı¨ve
patients with the initiation of ICS therapy [30]. Regarding
pregnancy, it may be a part of pregnancy-related immune
tolerance. Clusterin levels increase in preeclampsia, even
prior to onset, so it may also serve as a predictivemarker [33].
In the present study, we aimed to investigate osteopontin
and clusterin levels in asthma and asthmatic pregnancy in
comparison with healthy nonpregnant control subjects and
healthy pregnant women.The possible relationships between
osteopontin, clusterin, and asthma control determinantswere
also evaluated.
2. Materials and Methods
2.1. Ethics Statement. Written informed consentwas obtained
from all subjects, and our study was reviewed and approved
by an independent ethical committee of the institution
(Institutional and Regional Research Ethics Committee of
Semmelweis Medical University). Laboratory studies and
interpretations were performed on coded samples lacking
personal and diagnostic identifiers. The study adhered to
the tenets of the most recent revision of the Declaration of
Helsinki.
2.2. Study Participants. In this cross-sectional study, 26 asth-
matic pregnant (AP) and 22 asthmatic nonpregnant (ANP)
women together with 25 healthy pregnant (HP) women and
12 healthy controls were enrolled. Asthmatic patients were
recruited at their regular visit at the outpatient clinic of the
Department of Pulmonology, Semmelweis University. They
had persistent disease and they were diagnosed according
to the current guidelines (GINA; [1]). Exclusion criteria
included the existence of any other chronic disease (except
for allergic rhinitis), multifetal gestation, maternal or fetal
infections within six weeks of measurement, and current
smoking (or more than 5-pack-year of smoking history).
The patients were asked not to use their medications 12
hours before their visits. Healthy pregnant subjects were
enlisted when attending their scheduled visit (mostly in
the third trimester of pregnancy) at the 1st Department of
Obstetrics and Gynecology, Semmelweis University. Healthy,
nonpregnant controls were volunteer blood donors, with a
negative history and negative status upon detailed physical
and routine laboratory examination.
2.3. Laboratory Procedures. Plasmaosteopontin and clusterin
concentrations were measured with the Human Osteopontin
(OPN) Quantikine ELISA Kit (RD-DOST00) and with the
Human Clusterin Quantikine ELISA Kit (RD-DCLU00),
respectively (R&D Systems, Inc., Minneapolis, USA), at the
Central Laboratory of Department of Laboratory Medicine.
Plasma was isolated from EDTA anticoagulated blood sam-
ples between 3 and 8∘C within 30 minutes after sampling and
stored at −80∘C until measurement as recommended by the
manufacturer.
2.4. Lung Function Measurement and Asthma Control Evalu-
ation. Lung function tests were performed by means of elec-
tronic spirometer (PDD-301/s, Piston, Budapest, Hungary),
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Table 1: Clinical data and inflammatory parameters of the four study groups (median [interquartile range]).
HNP (𝑛 = 12) HP (𝑛 = 25) ANP (𝑛 = 22) AP (𝑛 = 26)
Age (years) 29.5 [26.25–37] 34 [29.5–35.5] 35 [28.5–38.25] 31.5 [26–34]
Gestational age at sampling
(weeks) NA 35 [32.5–37] NA 24.5 [19–34.25]
Gestational age at delivery
(weeks) NA 39 [38–40] NA 38 [37–39]
𝑛=21
Fetal birth weight (grams) NA 3240 [2970–3730] NA 3250 [2995–3745]𝑛=21
FEV1 (% of predicted) NA NA 97 [92–108]
𝑛=21 94 [84.75–104.3]
PEF (% of predicted) NA NA 98 [81–99.5]𝑛=21 84.50 [75.25–103.5]𝑛=24
𝑅aw (% of predicted) NA NA 118 [97–171.5]
𝑛=21 105 [73–129]𝑛=23
FEF 25–75% (% of
predicted) NA NA 77 [63.5–93]
𝑛=21 83 [64–104]𝑛=23
ACT total score NA NA 24 [20.5–25]𝑛=21 22 [19–25]𝑛=24
Daily dose of ICS
(beclomethasone
equivalent, 𝜇g)
NA NA 200 [0–1000] 650 [0–1000]
Eosinophil cells (%) 1.595 [1.260–2.478] NA 2.420 [1.273–6.553]𝑛=14 2 [1.218–3.060]𝑛=20
IL-6 (pg/mL) NA NA 1.795 [1.500–2.278]𝑛=20 1.935 [1.5–3.433]𝑛=22
CRP (mg/mL) 3.0 [1.3–3.0]𝑛=11 NA 3 [3–5]𝑛=21 4.845 [3–8.750]𝑛=24
Osteopontin (ng/mL) 2.075 [1.680–2.331] 3.037 [2.439–4.015]a 2.086 [1.508–2.679]b 2.693 [1.581–3.620]
Clusterin (𝜇g/mL) 108.8 [97.94–115.3] 98.80 [84.26–105.5]a 109.2 [95.59–116.3]b 111.7 [98.84–125.6]b
HNP: healthy nonpregnant; HP: healthy pregnant; ANP: asthmatic nonpregnant; AP: asthmatic pregnant; FEV1: forced expiratory volume in 1 second; PEF:
peak expiratory flow rate; 𝑅aw : airway resistance; FEF25–75%: forced expiratory flow at 25–75% of forced vital capacity; ACT: asthma control test; ICS: inhaled
corticosteroid; CRP: C-reactive protein; IL-6: interleukin-6; NA: not applicable. a𝑝 < 0.05 versus HNP; b𝑝 < 0.05 versus HP.
according to the AmericanThoracic Society (ATS) guidelines
[34]. After three technically acceptable manoeuvres, we were
using the one with the best results. Forced expiratory volume
in one second (FEV1), peak expiratory flow (PEF), and airway
resistance (𝑅aw) weremeasured. Asthma control was assessed
using the asthma control test (ACT), suggested by the current
(GINA) guidelines [1].
2.5. Statistics. Data distribution was analyzed by D’Agostino-
Pearson normality test. Comparisons between the study
groups were made with Kruskal-Wallis and Dunn’s post hoc
multiple comparison tests. Correlation analyses were per-
formed using Spearman’s test due to nonnormal distribution
of data. Area under the curve (AUC) values of receiver
operating characteristics (ROC) curves were calculated using
standardmethods and data are presented as AUC-ROC (95%
CI). 𝑝 values < 0.05 were considered significant. Statistics
were calculated using theGraphPadPrism software 6 (Graph-
Pad Software, La Jolla, CA, USA). Data are expressed as
median [interquartile range]. Sample size was estimated to
find relevant differences (effect size of 0.40 and power of 0.80)
among the four groups in case of the two examinedmediators
(osteopontin and clusterin) with respect to the asymptotic
relative efficiency of nonparametric tests.
3. Results
3.1. Clinical Characteristics. All of the gathered clinical
and demographical data and the measured inflammatory
parameters of the subjects are summarized in Table 1. Ages
of participants were comparable among the four groups.
Gestational age at blood sampling was lower in the AP than
in the HP group (24.5 [19–34.25] versus 35 [32.5–37] weeks,
𝑝 = 0.0002). Gestational age at delivery and fetal birth weight
were comparable in the two pregnant groups.
No difference was detected either in the severity or
control of asthma or the daily dose of inhaled corticosteroids
(ICS) between the ANP and AP groups (Table 1). 11 asthmatic
nonpregnant and 17 asthmatic pregnant patients received
ICS treatment, while 11 patients in the ANP group and 9
patients in the AP group were steroid-naı¨ve. Steroid-naı¨ve
and steroid-treated patients did not differ in any of the inves-
tigated parameters (such as spirometry results, ACT total
scores, inflammatory parameters, and peripheral eosinophil
cell counts). ACT total scores (24 [20.5–25]𝑛=21 in the ANP
and 22 [19–25]𝑛=24 in the AP group) showed acceptable
and similar levels of disease control of the patients in both
asthmatic groups. 2 ANP and 3 AP patients were nonallergic
asthmatics; all the other asthmatic patients suffered from
allergic/atopic disease.
3.2. Comparison of Circulating Marker Levels among the Four
Groups. Pregnancy per se caused elevation in circulating
osteopontin level, as it was significantly higher in the HP
than in the HNP group (3.037 [2.439–4.015] versus 2.075
[1.680–2.331] ng/mL, 𝑝 = 0.0036). In asthmatic subjects,
this difference only reached the level of a trend (2.693
[1.581–3.620] in AP versus 2.086 [1.508–2.697] ng/ml in



















Figure 1: Circulating osteopontin levels in healthy nonpregnant and
pregnant and in asthmatic nonpregnant and pregnant subjects (data
are expressed as median [interquartile range]). HNP: healthy non-
pregnant; HP: healthy pregnant; ANP: asthmatic nonpregnant; AP:
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Figure 2: Positive correlation of gestational weeks at sampling to
circulating osteopontin in asthmatic pregnant patients. 𝑝 < 0.0001;
𝑟 = 0.6924.
ANP, 𝑝 = 0.0850). Osteopontin levels of the two pregnant
groups did not differ (3.037 [2.439–4.015] ng/mL in HP
versus 2.693 [1.581–3.620] ng/mL in AP, 𝑝 = 0.3541), and
the data of ANP and HNP subjects were similar as well (2.142
[1.483–2.701] versus 2.075 [1.680–2.331] ng/mL, 𝑝 = 0.7331,
Figure 1).
Circulating osteopontin correlated positively with the
gestational age at sampling in the AP group (𝑟 = 0.6921; 𝑝 <
0.0001; Figure 2).
Asthma itself also did not influence circulating clus-
terin level, as ANP and HNP groups had similar results
(109.2 [95.59–116.3] versus 108.8 [97.94–115.3] 𝜇g/mL, 𝑝 =
0.8730). On the other hand, circulating clusterin levels
were significantly lower in the HP than in the HNP group
(98.80 [84.26–105.5] versus 108.8 [97.94–115.3] 𝜇g/mL, 𝑝 =
0.0344). Since this pregnancy-specific decrease was absent
in AP group (AP 111.7 [98.84–125.6] versus ANP 109.2
[95.59–116.3] 𝜇g/mL), we could demonstrate a significant

















Figure 3: Circulating clusterin levels in healthy nonpregnant and
pregnant and in asthmatic nonpregnant and pregnant subjects (data
are expressed as median [interquartile range]). HNP: healthy non-
pregnant; HP: healthy pregnant; ANP: asthmatic nonpregnant; AP:
asthmatic pregnant. a𝑝 < 0.05 versus HNP; b𝑝 < 0.05 versus HP.















Figure 4: Positive correlation of subjects’ age to circulating clusterin
levels in asthmatic pregnant patients. 𝑝 = 0.0442; 𝑟 = 0.3978.
groups (111.7 [98.84–125.6] 𝜇g/mL in AP versus 98.80
[84.26–105.5] 𝜇g/mL inHP,𝑝 = 0.0091; Figure 3 andTable 1).
Circulating clusterin level correlated positively with the
age of the patients in the AP group (𝑝 = 0.0442; 𝑟 = 0.3978;
Figure 4).
3.3. Relationship of Inflammatory Markers to Asthma Control
Determinants and Obstetrical Data. For spirometry results,
we observed a positive correlation between PEF and circu-
lating clusterin levels (𝑟 = 0.4487; 𝑝 = 0.0413; Figure 5)
and a negative correlation in case of 𝑅aw and circulating
clusterin (𝑟 = −0.4764; 𝑝 = 0.0290; Figure 6) levels in
the ANP group. This association remained significant even
when we merged the AP and ANP groups and investigated
it in the whole asthmatic cohort (PEF: 𝑟 = 0.3405 and 𝑝 =
0.0221; 𝑅aw: 𝑟 = −0.3723 and 𝑝 = 0.0128). There were
no correlations observed between any of the investigated
inflammatory markers and the obstetrical parameters in the
pregnant groups. Besides that, circulating osteopontin and
















Figure 5: Positive correlation of PEF and circulating clusterin levels

















Figure 6: Negative correlation of 𝑅aw and circulating clusterin levels
in asthmatic patients (pregnant and nonpregnant). 𝑝 = 0.0128; 𝑟 =
−0.3723.
clusterin levels were not influenced by the daily inhaled
corticosteroid dose of the patients.
As current guideline [1] defines uncontrolled asthma as
a disease with PEF below 80% predicted or ACT total score
below 20, ROC analyses of asthmatic patients’ data were
performed in case of both mediators in subgroups of AP and
ANP with PEF above and below 80% and ACT total score
above and below 20. However, these analyses did not yield
any statistically significant results.
4. Discussion
The aim of this study was to assess plasma osteopontin and
clusterin levels in asthmatic pregnancy together with healthy
and asthmatic nonpregnant and healthy pregnant sub-
jects. Furthermore, we examined any possible relationships
between these markers and asthma control determinants.
We demonstrated an increase of osteopontin level in both
pregnant groups compared with the nonpregnant respective
ones; however, in asthmatic pregnancy, no further elevation
was detected compared to healthy pregnancy. Thence, con-
comitant mostly well-controlled asthma did not influence
circulating osteopontin level during pregnancy. Regarding
circulating clusterin level, we observed a decrease in healthy
pregnancy; however, this pregnancy-specific decrease was
absent in asthmatic pregnantwomen. Furthermore, a positive
correlation was detected between PEF and clusterin, and a
negative correlation was detected between 𝑅aw and clusterin
levels in asthmatic nonpregnant patients.
Themost important limitation of our study was the small
sample size. Furthermore, our datamay be confounded by the
well-controlled state of nearly all enrolled asthmatic patients
and thus may not represent a general asthmatic population.
The reason for this is our clinical goal to achieve the
best control of the disease (especially in pregnant patients).
Nevertheless, our data must be considered with caution due
to these limitations.
Osteopontin emerged as a promising inflammatory
biomarker because of its multifunctional role in a wide range
of inflammatory processes. It functions as an extracellular
matrix protein and immune modulator, expressed by many
cell types, such as bronchial epithelial cells, T-cells, dendritic
cells, and eosinophils [11–16]. A number of studies demon-
strated the importance of osteopontin in the development
of several inflammatory diseases, particularly in connec-
tion with CD4+ T-helper-associated immune responses [11].
Firstly, it was identified as a key element of Th1 responses,
inducing IL-12 production inmacrophages anddendritic cells
in vitro. The dendritic cells activated by osteopontin were
shown to stimulate na¨ıve T-cells to produce Th1-polarized
cytokines. Osteopontin is involved in the pathogenesis of
several diseases associated with Th1 responses, including
rheumatoid arthritis, sarcoidosis, tuberculosis, Crohn’s dis-
ease, and multiple sclerosis [11]. Recently, some studies
investigated its role in bronchial asthma and allergic dis-
eases. Compared to healthy control subjects, higher levels of
osteopontin were measured in serum, sputum, and BALF of
asthmatic patients [13, 14], and the differences were shown
to be even more explicit in case of smoking asthmatics [23].
According to Hillas et al. [35], smoking habit significantly
affects sputum osteopontin levels in asthma. Increased osteo-
pontin levels were also observed in allergic conjunctivitis
[36] and allergic rhinitis [37]. However, in accordance with
our results, the increase does not seem to correlate with the
severity or control of asthma [22]. Studies of endobronchial
biopsies of asthmatic patients found increased osteopontin
levels and positive correlation between the tissue remod-
elling and the bronchial expression of osteopontin [17, 22].
There are controversial data about the relationship between
osteopontin levels and eosinophilia; while Liu et al. reported
elevated serum osteopontin levels in asthmatic patients [38],
a recent review suggests that osteopontin rather appears to
be related to a neutrophil asthma phenotype and indicates
disease severity [39]. Although there are studies that showed
elevated osteopontin levels in asthmatic patients, in our study,
this increasewas absent.This apparent contradiction between
our data and some of the previous resultsmay be based on the
different levels of the patient’s asthma control, as our patients
were mostly well controlled, with ACT scores of 22 or higher,
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and due to the fact that they mostly have eosinophil/atopic
asthma, which, based on the recent findings [39], shows less
connection with the peripheral osteopontin levels. However,
it must be stressed that one of the major limitations of our
study is the lack of uncontrolled, symptomatic asthmatics. It
also should be noted thatmost of the earlier studiesmeasured
osteopontin levels in sputum or bronchoalveolar lavage fluid
of asthmatic patients, and less studies measured the serum
levels.
On the other hand, osteopontin also has a wide variety
of functions in pregnancy, including a role as a component
involved in adhesion and signal transduction at the uterine-
placental interface, regulating immune cell behavior and
cytokine production and expression in the uterine stroma
[40, 41]. It has an essential role in the maintenance of a
successful pregnancy from the implantation of the blastocyst
[24, 25] until the end of gestation [26, 27].
Our study was the first to evaluate osteopontin levels in
asthmatic pregnancy. In line with earlier findings [26], we
were able to demonstrate an elevation of osteopontin levels
in healthy pregnant women, which correlated positively with
gestational age. There was a detectable but not significant
elevation in asthmatic pregnant women too, compared to
asthmatic nonpregnant patients. The absent of statistical
significance in the latter case is probably in connection with
one of the limitations of this study, more precisely the fact
that the gestational age at sampling in theAP groupwas lower
than that in the HP group. However, the connection between
osteopontin level and pregnancy suggests that osteopontin as
an asthma biomarker must be handled with caution during
pregnancy.
Clusterin is a sensitive cellular biosensor of oxidative
stress [30] which is an important factor in the pathophysi-
ology of asthma and also maternal asthma during pregnancy
[42, 43]. The function of clusterin in oxidative stress has not
been determined yet, but it is thought to protect cells from
oxidative injury [30, 32]. Clusterin levels are elevated inmany
different pathological conditions, like apoptosis, hypoxia,
or neurodegenerative conditions, and in several diseases,
such as diabetes and atherosclerosis, and treatment recurrent
cancers, including castrate resistant prostate cancer [28, 30,
44]. In line with earlier findings [30], we found a correlation
between plasma clusterin levels and age in the asthmatic
pregnant group. However, we could not confirm all the pre-
vious data [30], as we did not detect higher plasma clusterin
levels in asthmatic patients. The reason of this difference
could be the fact that, based on the almost physiological lung
function results and CRP levels, together with ACT scores
indicating nearly no symptoms, our asthmatic patients were
mostly well controlled, while increased clusterin levels were
mostly observed in patients with severe uncontrolled disease
[30]. Furthermore, contrary to some previous findings, in
which circulating clusterin levels showed inverse correlation
with the pulmonary function [30], we observed a significant
positive correlation of PEF and a negative correlation of
𝑅aw to circulating clusterin levels in asthmatic, nonpregnant
patients. This surprising result may also be the consequence
of one of the major limitations of our study, which is
the mostly well-controlled state of our patients, while in
previous studies, patients were uncontrolled. In controlled
patients, the dominant function of clusterin may be the
anti-inflammatory, protective function [32]; however, data
about clusterin are still scarce and its functions are not fully
elucidated yet.
Furthermore, many studies have shown elevated serum
and placenta clusterin levels in preeclamptic women [29,
33, 42, 43], elevation of which could be in connection with
endothelial cell injury or oxidative stress [43]; however,
serum clusterin level was never examined in asthmatic
pregnancy before. In a recent study, the elevation of clus-
terin levels was observed prior to onset of preeclampsia,
suggesting that it may also serve as a predictive marker of
adverse pregnancy outcomes [33]. In our study, we found
decreased plasma clusterin in healthy pregnant women, but
this decrease was absent in the asthmatic pregnant group.
This relative increase in asthmatic versus healthy pregnancy
may be the consequence of enhanced oxidative stress, which
characterizes asthma during pregnancy [42].
In conclusion, increase of osteopontin level in pregnancy
independently of concomitant asthma suggests that it has an
important role during gestation and indicates caution if used
as a biomarker in pregnant state. Clusterin level decreases
in healthy pregnant women; however, this decrease is absent
in asthmatic pregnancy, which may be related to asthmatic
inflammation. On the other hand, positive correlation of PEF
and negative correlation of 𝑅aw to circulating clusterin level
are probably the result of its anti-inflammatory effect in well-
controlled asthma; however, further research on circulating
clusterin level as an asthma biomarker in controlled versus
uncontrolled disease is warranted.
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